Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1347-1352, 2003; 10.1373/49.8.1347
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, L.
Right arrow Articles by Li, Y.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, L.
Right arrow Articles by Li, Y.-L.
Related Collections
Right arrow Nutrition
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2003;49:1347-1352.)
© 2003 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease

Ling Liu1,a, Shui-Ping Zhao1, Yan-Chun Cheng1 and Yu-Ling Li2

Departments of
1 Cardiology and
2 Nutrition, the Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, People’s Republic of China.

aAuthor for correspondence. Fax 086-731-4895989; e-mail lightbluerose{at}163.net.


   Abstract
Top
 Abstract
Introduction
 Participants and Methods
 Results
 Discussion
 References
 
Background: Increased serum lipoprotein(a) [Lp(a)] and high-sensitivity C-reactive protein (hsCRP) concentrations are independent risk factors for coronary heart disease (CHD). Xuezhikang, an extract of cholestin, effectively lowers fasting cholesterol and triglyceride concentrations. We studied whether xuezhikang lowered Lp(a) and hsCRP concentrations.

Methods: We randomly divided 60 CHD patients into two groups to receive xuezhikang (1200 mg daily) or placebo for 6 weeks. The fasting hsCRP concentration and the postprandial changes of serum lipid concentrations at 2, 4, and 6 h after a high-fat meal (800 calories; 50 g of fat) were measured before and after the 6-week protocol.

Results: The two groups had similar baseline fasting lipid and hsCRP concentrations. The postprandial triglyceride and Lp(a) concentrations were significantly increased (P <0.05). After 6 weeks, the fasting and postprandial lipid concentrations decreased significantly in the xuezhikang group, accompanied by a significant reduction in fasting hsCRP concentration (P <0.001). The placebo group had no significant change in lipid concentrations, whereas the fasting serum hsCRP concentration was reduced significantly (P <0.05). The reduction in hsCRP was closely related to the changes in fasting Lp(a) concentration (r = 0.402; P <0.05) and triglyceride area under the curve (r = 0.441; P <0.001).

Conclusions: Xuezhikang effectively decreased fasting Lp(a) and postprandial triglyceride concentrations, which were associated with reductions of fasting hsCRP concentrations in CHD patients.


   Introduction
Top
 Abstract
 Introduction
Participants and Methods
 Results
 Discussion
 References
 
The postprandial state is critical in atherogenesis. Abnormal metabolism of postprandial triglyceride-rich lipoproteins (TRLs)1 has been reported in patients with coronary heart disease (CHD) or risk factors (1). An association between postprandial increases in serum lipoprotein(a) [Lp(a)] concentrations and hypertriglyceridemia after fat intake has been observed in some studies (2)(3), although data from other studies were conflicting (4)(5). Increased plasma Lp(a) has been shown to be a risk factor for atherosclerosis (6)). Lp(a) resembles a LDL particle, but with the addition of apolipoprotein(a) [apo(a)], which is similar to plasminogen; therefore, Lp(a) is a link between atherosclerosis and thrombosis. Moreover, Lp(a) may be involved in atherogenesis through an inflammatory mechanism. Recent evidence has shown that Lp(a) is correlated with inflammatory factors (7)(8)(9)(10)(11), including C-reactive protein (CRP).

Increased CRP is an important predictor of cardiovascular events, independent of traditional risk factors (12). High-sensitivity CRP (hsCRP) assays are needed for the measurement of CRP concentrations to predict the risk of acute coronary events. Increased fasting hsCRP concentrations have been reported in patients with CHD and equivalent risk factors compared with controls (13)(14)(15). Results from an increasing number of studies suggest that CRP is not only a novel factor of cardiovascular risk (16)(17) but also a target or end-point for prevention and treatment of CHD in addition to lipid control (18).

The effect of hydroxymethylglutaryl-CoA reductase inhibitors (statins) on Lp(a) concentration is controversial. Most studies have shown that statins decrease plasma LDL-cholesterol (LDL-C) and CRP concentrations but not Lp(a) (19)(20)(21). Xuezhikang is an extract of cholestin that has been approved by the Food and Drug Administration as a Chinese red-yeast rice dietary supplement. It contains a family of monacolin-related substances, one of which is a naturally occurring lovastatin, in addition to unsaturated fatty acids and other substances (22)(23). Xuezhikang has been reported to markedly lower fasting total cholesterol and triglyceride concentrations (22)(23)(24), but little attention has been directed to a possible effect on serum hsCRP and Lp(a) concentrations. This study was designed to explore the changes in serum Lp(a) concentrations after a high-fat meal and the effects of xuezhikang on hsCRP and Lp(a) concentrations in CHD patients before and after a 6-week treatment with xuezhikang.


   Participants and Methods
Top
 Abstract
 Introduction
 Participants and Methods
Results
 Discussion
 References
 
participants
The study included 60 CHD patients who were admitted to our hospital between October 2001 and June 2002. CHD was diagnosed as a history of myocardial infarction and/or angiographically confirmed coronary atherosclerosis in patients with angina pectoris. Their dietary habits, including food content and amounts, and daily activity were investigated by use of the Nutrition and Health Questionnaire. The research protocol was approved by the Ethics Committee of Central South University. All participants gave fully informed consent before study entry.

All patients were in New York Heart Association class I or II and had no chest pain within the previous month. No patient had a history of diabetes, thyroid diseases, liver or kidney disease, malignancy, chronic consuming diseases, dyspepsia, or malabsorption. No patient took oral agents for hyperglycemia or hyperlipidemia. All patients refrained use of from ß-blockers and diuretics for a week and from nitrates, intravenous infusion, smoking, alcohol, and a fat-rich diet for 24 h before the high-fat meal.

experimental protocol
At the end of a 4-week dietary advisory period, all patients were randomly divided into two groups to receive 600 mg of xuezhikang (300 mg of cholestin per capsule; WBL Peking University Biotech Co., Ltd) twice daily (xuezhikang group; n = 30) or placebo (placebo group; n = 30) after the first high-fat meal. The total study period was 6 weeks, at which time the oral high-fat tolerance test was repeated. All patients maintained a stable diet in terms of types and amounts of food according to dietary advice and took routine medications, including aspirin (100 mg/day), metoprolol, fosinopril, and nitrates during follow-up. Patients were not allowed to take other lipid-lowering drugs, vitamin supplements, or unsaturated fatty acids during the entire study period.

oral high-fat tolerance test
All patients attended the hospital at 0700–0800 after a 12-h overnight fast. The oral high-fat tolerance test was undertaken as performed previously in our hospital by special nutritionists. The high-fat meal consisted of 800 calories with 50 g of fat (5 g of saturated fat, 345 mg of cholesterol), 28 g of protein, and 60 g of carbohydrates (25). The meals given for the fat tolerance studies were not adjusted for the weight of the participants because they had similar body mass indices. All participants finished the high-fat meal within 15 min. During the next 6 h, participants were allowed to drink only water and not to smoke, drink wine, or eat any foods. Only slow walking was allowed. Administration of oral drugs and intravenous infusions was prohibited until the last blood sample was collected. Patients who could not tolerate this test were excluded.

lipid measurements
Venous blood samples were collected before and 2, 4, and 6 h after the high-fat meal. Serum was separated at 4 °C and then stored at -30 °C. Serum total cholesterol, triglyceride, HDL-cholesterol (HDL-C), LDL-C, and Lp(a) concentrations were measured on a HITACHI 7170A analyzer by a specialist who was unaware of the study. Serum total cholesterol and triglyceride concentrations were measured by enzymatic methods, and HDL-C and LDL-C concentrations were measured by direct methods. The Lp(a) concentration was measured by an immunoturbidimetric method. The reagents were provided by Daiichi Pure Chemicals Co., Ltd. The inter- and intraassay CVs were controlled within 5.5% and 3.5%, respectively.

hsCRP MEASUREMENTS
Fasting hsCRP was measured at 550 nm by a particle-enhanced immunoturbidimetric assay (Orion Diagnostica) on a HITACHI 7170A analyzer. The lower limit of detection for the method is 0.125 mg/L. The measurement range for hsCRP was 0.20–2.94 mg/L. The interassay CVs were 0.14% and 2.1% at mean values of 8.20 and 0.31 mg/L, respectively, and the intraassay coefficients of variation were 0.13% and 2.3% at mean values of 8.21 and 0.30 mg/L, respectively.

statistical analysis
Data were analyzed with SPSS (Ver. 10.0) and are presented as the mean (SD) unless other indicated. Lp(a) results are presented as the mean (SE). Because the hsCRP distribution was skewed, it is shown on the original scale [median (lower-upper quartile)] and log-transformed for distribution-dependent analyses. Differences between the intra- and intergroup means were analyzed by t-test or one-way ANOVA. Coefficients of correlation (r) were calculated by Pearson correlation analysis. General linear regression analysis with adjustment for differences in baseline variates was performed to assess the effect of xuezhikang treatment. The triglyceride and Lp(a) areas under the curve over the fasting concentration [TG-AUC and Lp(a)-AUC] were calculated by the trapezoidal method. Statistical significance was defined as P <0.05.


   Results
Top
 Abstract
 Introduction
 Participants and Methods
 Results
Discussion
 References
 
There were no significant differences in clinical characteristics or fasting serum lipid and hsCRP concentrations between the patients in the xuezhikang group and placebo group (Table 1 ).


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical characteristics of two groups of CHD patients.1

The serum total cholesterol, LDL-C, and HDL-C concentrations did not change significantly in postprandial period (data not shown), whereas the postprandial serum triglyceride and Lp(a) concentrations increased significantly and peaked at 4 h after a high-fat meal (P <0.05). The xuezhikang and placebo groups had similar postprandial changes in serum Lp(a) and triglyceride concentrations (Table 1Up and Figs. 1 and 2 ).



View larger version (11K):
[in this window]
[in a new window]
  		Figure 1. Changes in fasting and postprandial Lp(a) concentrations after a high-fat meal in the xuezhikang (•) and placebo ({circ}) groups before and after 6 weeks of treatment.

Solid lines indicate baseline values for both groups; dashed lines indicate values after 6 weeks of treatment. *, P <0.05 compared with the fasting Lp(a) concentration; #, P <0.05 compared with the baseline Lp(a) concentration at the same time point.



View larger version (12K):
[in this window]
[in a new window]
  		Figure 2. Changes in fasting and postprandial triglyceride concentrations after a high-fat meal in the xuezhikang ({blacktriangleup}) and placebo ({triangleup}) groups before and after 6 weeks of treatment.

Solid lines indicate baseline values for both groups; dashed lines indicate values after 6 weeks of treatment. *, P <0.05 compared with the fasting triglyceride concentration. #, P <0.05 compared with the baseline triglyceride concentration at the same time point.

After a 6-week treatment with xuezhikang, the fasting triglyceride, total cholesterol, LDL-C, and Lp(a) concentrations decreased by 25%, 21%, 30%, and 23%, respectively (P <0.05), and the HDL-C concentration increased by 16% (P <0.05). The postprandial serum triglyceride and Lp(a) concentrations at all time points (2, 4, and 6 h) and the Lp(a)-AUC [to 64.3 (37.9) mmol/L · 6 h] and TG-AUC [to 3.14 (2.08) mmol/L · 6 h] decreased significantly (P <0.001; Figs. 1Up and 2Up ) in the xuezhikang group, accompanied by a significant reduction in fasting hsCRP concentration [to 0.70 (0.25–1.35) mg/L; P <0.001].

There was no significant change in fasting and postprandial serum lipid concentrations at the end of 6 weeks in the placebo group (data not shown), whereas the fasting serum hsCRP concentration was reduced significantly [to 1.90 (1.50–2.45) mg/L; P <0.05].

Linear regression analysis showed that xuezhikang treatment significantly and independently predicted the changes in fasting triglyceride, total cholesterol, LDL-C, HDL-C, and hsCRP concentrations and in TG-AUC and Lp(a)-AUC (P <0.05).

We found a correlation between the fasting serum Lp(a) and hsCRP concentrations (r = 0.318; P <0.05). The change in TG-AUC was correlated with that of Lp(a)-AUC (r = 0.398; P <0.01). The decrease in the fasting serum hsCRP concentration was closely related to the changes in the fasting Lp(a) concentration (r = 0.402; P <0.05) and TG-AUC (r = 0.441; P <0.001), but not to the changes in the fasting serum total cholesterol, triglyceride, HDL-C, and LDL-C concentrations and in Lp(a)-AUC.


   Discussion
Top
 Abstract
 Introduction
 Participants and Methods
 Results
 Discussion
References
 
The postprandial state is important in atherogenesis because of the increased risk of postprandial hyperlipidemia and accompanying abnormalities. Postprandial hyperlipidemia not only includes postprandial hypertriglyceridemia but also may involve increased serum Lp(a) concentrations. Plasma Lp(a) concentrations vary greatly among individuals, whereas the Lp(a) concentration for each individual seems to be constant and invariable in response to diet, even in CHD patients (4). However, some studies have demonstrated an acute increase in plasma Lp(a) after an oral fat load (2)(3). In hyperlipidemic patients, the postprandial plasma Lp(a) concentrations increased transiently at 4.5 h, decreased between 4.5 and 12 h, and recovered almost to initial concentrations by the next morning (2). We also observed a postprandial increase in serum Lp(a) concentrations, which reached a peak value at 4 h, the same time point as the postprandial triglyceride peak in CHD patients, and had no sharp decrease even at 6 h. These data indicate that there is a close relationship between the postprandial metabolism of TRLs and Lp(a).

The majority of apo(a) in plasma is characteristically associated with Lp(a). In the postprandial state, a small proportion of plasma apo(a) is found in the d <1.006 kg/L fraction of plasma by density gradient ultracentrifugation, associated with larger and less dense TRLs (26). Moreover, apo(a) in the TRLs fraction increased, whereas apo(a) in the d >1.006 fraction decreased after fat intake, suggesting a transfer of apo(a) from the d >1.006 fraction to the TRLs (2). Evidence supports that apo(a) in the TRL fraction of individuals with postprandial hypertriglyceridemia is not an integral component of plasma VLDL or chylomicrons, but represents the presence of noncovalently bound Lp(a) (26). Recently, Nassir et al. (27) observed that apo(a) secretion from hepatoma cells may be linked to elements of cellular triglyceride assembly and secretion, which raises the idea that the Lp(a) concentration in humans may be affected by alterations in the hepatic synthesis of TRLs. Because postprandially increasing TRLs are partly secreted by the liver, it would be anticipated that the change in the postprandial Lp(a) concentration was correlated with that of the postprandial triglyceride concentration in this study.

Investigations of the influence of statin therapy on Lp(a) concentrations are controversial. The Lp(a) concentration responds well to estrogen (28) and nicotinic acid (29)(30) but not to statins, which effectively lower plasma cholesterol concentrations, with some studies showing an increase (31)(32) and others showing no effect on Lp(a) concentration (19)(20)(21). Xuezhikang contains a family of monacolin-related substances, one of which is a naturally occurring lovastatin (22)(23). However, the effect of lovastatin on Lp(a) is uncertain (30)(33). It has been reported that xuezhikang has a prominent lipid-modulating effect on the fasting total cholesterol, triglyceride, LDL-C, and HDL-C concentrations (22)(23)(24), which is consistent with our results. In the present study, xuezhikang reduced the fasting Lp(a) concentration as well as the postprandial Lp(a) and triglyceride concentrations, although the lipid-modulating mechanism may be complex.

A recent study in patients with atherosclerotic disease demonstrated that small doses of aspirin (81 mg/day) effectively decreased serum Lp(a) concentrations in patients with high Lp(a) concentrations (>300 mg/L) but not in those with low Lp(a) concentrations (<300 mg/L) (34). Similarly, in the present study we observed no significant change in Lp(a) concentrations as a result of routine treatment with aspirin (100 mg/day) for most of CHD patients with low Lp(a) concentrations (<300 mg/L).

It has been recognized that dyslipidemia and inflammation interact and play crucial roles in atherogenesis. Postprandial hypertriglyceridemia can induce a high inflammatory state in the circulation. The expression and concentrations of proinflammatory cytokines, such as tumor necrosis factor-{alpha}, interleukin-1ß, and interleukin-6, are increased after a fat meal, and the increase in cytokines concentrations was related to increases in postprandial triglyceride concentrations (35)(36). This suggests that eliminating postprandial hypertriglyceridemia may be helpful in inhibiting chronic inflammation. Chronic inflammation characterized by increased CRP concentrations strongly predicts cardiovascular disease and acute coronary events in patients with CHD and risk factors (12)(18). We found that hsCRP concentrations were closely correlated with Lp(a) concentrations in CHD patients. Lp(a) may act as an acute-phase reactant (24) and thus possibly contribute to acute cardiac events. Moreover, many studies have demonstrated a significant relationship between Lp(a) and CRP (13)(14) and other inflammatory factors, such as fibrinogen, interleukin-6 (7), complement 3 and 4 (8), and soluble cellular adhesion molecules(9), which suggests that Lp(a) may be involved in atherogenesis through an inflammatory mechanism.

The serum CRP concentration not only serves as an independent predictive factor for atherosclerotic cardiovascular diseases (12) but also as an indicator for estimating the effectiveness of treatment (18). It has been reported that statins have direct antiinflammatory effects on CRP concentration, which seem to be independent of their lipid-modulating effects in the fasting state (37)(38). In the present investigation, hsCRP concentrations in the xuezhikang group decreased significantly, although the placebo group also showed a mild reduction that could be attributed to aspirin, beta-blockers, and fosinopril, which have antiinflammatory effects. We found no relationship between the change in hsCRP concentration and the changes in fasting lipids, including total cholesterol, triglycerides, LDL-C, and HDL-C, but the decreases in fasting Lp(a) and postprandial triglyceride concentrations were significantly correlated with decreases in hsCRP in CHD patients, which had not been reported in previous studies (37)(38). This result suggests that xuezhikang may control chronic inflammation partly through an indirect antiinflammatory effect that results from lipid-lowering and other processes that reduce triggers and stimulators, rather than the direct antiinflammatory effect from the naturally occurring statin-like elements.

This study was a clinical investigation, and further research is needed to explore the lipid-modulating mechanisms of xuezhikang. However, xuezhikang contains a family of naturally occurring statins (monacolins), one of which is lovastatin. It has been demonstrated that lovastatin, as well as other statins, lowers serum total lathosterol concentrations and inhibits cholesterol synthesis (39)(40). Thus, xuezhikang could have a similar effect on cholesterol synthesis, although its triglyceride-lowering mechanism is unclear.

Serum Lp(a) and hsCRP concentrations measured by immunoturbidimetric method may be interfered with by triglycerides. However, the highest fasting and postprandial triglyceride concentrations were 3.20 and 6.98 mmol/L, respectively, which are far lower than the extreme concentrations that affect Lp(a) and hsCRP assays. Thus, the association of CRP and Lp(a) with increased triglycerides could reflect a true physiologic phenomenon.

In conclusion, xuezhikang not only effectively decreased the fasting hsCRP and Lp(a) concentrations but also reduced the postprandial Lp(a) and triglyceride concentrations in CHD patients. Moreover, xuezhikang may modulate CRP secretion partly through a lipid-lowering mechanism.


   Acknowledgments
 
We thank all those who participated in this study. We also thank Dr. Dahan Tang and HaiQiu Wu for support on the nutrition design, Dr. Ming Hu for serum lipid and hsCRP measurements, and the department of clinical laboratory technique in the second Xiangya hospital for assistance.


   Footnotes
 
1 Nonstandard abbreviations: TRL, triglyceride-rich lipoprotein; CHD, coronary heart disease; Lp(a), lipoprotein(a); apo(a), apolipoprotein(a); hsCRP, high-sensitivity CRP; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; TG-AUC, triglyceride area under the curve; and Lp(a)-AUC, Lp(a) area under the curve.


   References
Top
 Abstract
 Introduction
 Participants and Methods
 Results
 Discussion
 References
 

  1. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ 1996;312:936-939.
  2. Ishikawa T, Yamashita T, Mochizuki K, Suzuki K, Hashizume N, Nakamura H. Changes in the concentration and distribution of lipoprotein(a) in plasma after fat intake. J Atheroscler Thromb 1995;2:S17-S21.
  3. Scanu AM, Edelstein C, Fless GM, Eisenbart J, Sitrin M, Kasawa B, et al. Postprandial lipoprotein(a) response to a single meal containing either saturated or omega-3 polyunsaturated fatty acids in subjects with hypoalphalipoproteinemia. Metabolism 1992;41:1361-1366.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  4. Hoppichler F, Kraft HG, Sandholzer C, Lechleitner M, Patsch JR, Utermann G. Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease, but does not change acutely following oral fat ingestion. Atherosclerosis 1996;122:127-134.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  5. Pfaffinger D, Schuelke J, Kim C, Fless GM, Scanu AM. Relationship between apo[a] isoforms and Lp[a] density in subjects with different apo[a] phenotype: a study before and after a fatty meal. J Lipid Res 1991;32:679-683.[Abstract]
  6. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52:254-261.[ISI][Medline] [Order article via Infotrieve]
  7. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 2002;40:1230-1239.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  8. Gurbuz O, Ozdemir Y, Cosar CB, Kural G. Lipoprotein(a) in Behçet’s disease as an indicator of disease activity and in thrombotic complications. Eur J Ophthalmol 2001;11:62-65.[ISI][Medline] [Order article via Infotrieve]
  9. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000;15:1624-1630.[Abstract/Free Full Text]
  10. Stenvinkel P, Heimburger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998;53:1336-1342.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  11. Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M. High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost 1995;74:1020-1024.[ISI][Medline] [Order article via Infotrieve]
  12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.[Abstract/Free Full Text]
  13. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-2912.[Abstract/Free Full Text]
  14. Rallidis LS, Zolindaki MG, Manioudaki HS, Laoutaris NP, Velissaridou AH, Papasteriadis EG. Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina. Clin Cardiol 2002;25:505-510.[ISI][Medline] [Order article via Infotrieve]
  15. Mojiminiyi O, Abdella N, Moussa M, Akanji A, Al Mohammedi H, Zaki M. Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;58:37.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  16. Gotto AM, Jr. Statins and C-reactive protein: considering a novel marker of cardiovascular risk. Prev Cardiol 2002;5:200-203.[Medline] [Order article via Infotrieve]
  17. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001;47:403-411.[Abstract/Free Full Text]
  18. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.[Abstract/Free Full Text]
  19. Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids 2002;37:439-444.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  20. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002;39:283-290.[ISI][Medline] [Order article via Infotrieve]
  21. Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, et al. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. Nutr Metab Cardiovasc Dis 1999;9:234-243.[ISI][Medline] [Order article via Infotrieve]
  22. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-236.[Abstract/Free Full Text]
  23. Jian JB, Hao XY, Deng CQ, Zhou HT, Lin J. The effects of xuezhikang on serum lipid profile, thromboxane A(2) and prostacyclin in patients with hyperlipidemia. Zhonghua Nei Ke Za Zhi 1999;38:517-519.[Medline] [Order article via Infotrieve]
  24. Kou WR, Lu ZL, Guo JX, Li HY, Xue SW, Lin YZ, et al. Effect of xuezhikang on the treatment of primary hyperlipidemia. Zhonghua Nei Ke Za Zhi 1997;36:529-531.[Medline] [Order article via Infotrieve]
  25. Liu L, Zhao SP, Gao M, Zhou QC, Li YL, Xia B. Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal. Clin Cardiol 2002;25:219-224.[ISI][Medline] [Order article via Infotrieve]
  26. Marcoux C, Lussier-Cacan S, Davignon J, Cohn JS. Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects. Biochim Biophys Acta 1997;1346:261-274.[Medline] [Order article via Infotrieve]
  27. Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 1998;273:17793-17800.[Abstract/Free Full Text]
  28. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.[Abstract/Free Full Text]
  29. Hoogerbrugge N, Jansen H, De Heide L, Zillikens MC, Deckers JW, Birkenhager JC. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. J Intern Med 1998;243:151-156.[Medline] [Order article via Infotrieve]
  30. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial Arch Intern Med 1994;154:1586-1595.[Abstract]
  31. Galetta F, Sampietro T, Basta G, Giannasi G, Bionda A. Effects of simvastatin on blood levels of lipoprotein(a). Minerva Med 1995;86:299-303.[Medline] [Order article via Infotrieve]
  32. Branchi A, Rovellini A, Fiorenza AM, Sommariva D. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein(a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther 1995;33:345-350.[ISI][Medline] [Order article via Infotrieve]
  33. Dobs AS, Prasad M, Goldberg A, Guccione M, Hoover DR. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. Cardiovasc Drugs Ther 1995;9:677-684.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  34. Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, et al. Effects of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48:1454-1459.[Abstract/Free Full Text]
  35. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145-1150.[Abstract/Free Full Text]
  36. Hyson DA, Paglieroni TG, Wun T, Rutledge JC. Postprandial lipemia is associated with platelet and monocyte activation and increased monocyte cytokine expression in normolipemic men. Clin Appl Thromb Hemost 2002;8:147-155.[Abstract/Free Full Text]
  37. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-1452.[Abstract/Free Full Text]
  38. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002;48:877-883.[Abstract/Free Full Text]
  39. Duane WC. Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. J Lipid Res 1995;36:343-348.[Abstract]
  40. Vanhanen H, Miettinen TA. Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia. Eur J Clin Pharmacol 1992;42:127-130.[CrossRef][ISI][Medline] [Order article via Infotrieve]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, L.
Right arrow Articles by Li, Y.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, L.
Right arrow Articles by Li, Y.-L.
Related Collections
Right arrow Nutrition
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS